Study title:
Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study.Speders S, Sosna J, Schumacher A, Pfennigsdorf G. Journal of cardiovascular pharmacology, 1989, vol. 13 Suppl 4, p. S47−9,Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study.Speders S, Sosna J, Schumacher A, Pfennigsdorf G. Journal of cardiovascular pharmacology, 1989, vol. 13 Suppl 4, p. S47−9,
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Cardiovascular Diseases
|
Brands: Please see report |
MAH holders: Please see report, Please see report |
Assessment: |
Active substance: VERAPAMIL |
ATC code: C08D A01 |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|